Moreover, trabectedin inhibited the expression of interferon regulatory factor 4 (IRF4), IKAROS family zinc finger 1 (IKZF1) and the miR-17 family (pri-miR-17-92, miR-17, and miR-20a) in MM cells, resulting in the upregulation of MICA, MICB, and ULBP1, ligands of natural killer (NK) cell activating receptor NKG2D, which ultimately lead to the activation and degranulation of NK cells (Cuce et al., 2019). The gene discussed is IRF4; the disease is Miyoshi myopathy.